WuXi Biologics (Cayman) 관리

관리 기준 확인 2/4

WuXi Biologics (Cayman) CEO는 Chris Chen, Jan2016 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 CN¥ 96.91M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 207.15M 가치에 해당하는 회사 주식의 0.35% 직접 소유합니다. 207.15M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 7.2 년입니다.

주요 정보

Chris Chen

최고 경영자

CN¥96.9m

총 보상

CEO 급여 비율	4.1%
CEO 임기	8.8yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Chen 의 보수는 WuXi Biologics (Cayman) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

보상 대 시장: Chris 의 총 보상 ($USD 13.39M )은 Hong Kong 시장( $USD 868.11K ).

보상과 수익: Chris 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Chris Chen (51 yo)

8.8yrs

테뉴어

CN¥96,911,000

보상

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

리더십 팀

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.8yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% HK$ 207.2m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% HK$ 7.9m
Ming Tu	CFO & Executive VP	3yrs	데이터 없음	데이터 없음
Lihua Yu	COO & Senior VP	less than a year	데이터 없음	데이터 없음
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	데이터 없음	데이터 없음
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	데이터 없음	데이터 없음
Lina Fan	Senior VP & Head of Investor Relations	less than a year	데이터 없음	데이터 없음
He Wang	Chief Compliance Officer	2.2yrs	데이터 없음	데이터 없음
Li Xiong	VP & Head of Global Human Resources	no data	데이터 없음	데이터 없음
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	데이터 없음	데이터 없음
Keqiang Shen	Chief Digital Officer	4.8yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: 2269 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.8yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% HK$ 207.2m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% HK$ 7.9m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% HK$ 369.8k
James Larrick	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
David D. Ho	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% HK$ 311.1k
Yanling Cao	Non-Executive Director	8.5yrs	데이터 없음	데이터 없음
Yibing Wu	Non-Executive Director	8.5yrs	데이터 없음	데이터 없음
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% HK$ 2.9m

7.2yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: 2269 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

WuXi Biologics (Cayman) 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO & Executive Director recently sold HK$6.6m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week